Literature DB >> 6141436

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival.

C Sauter, W Berchtold, M Fopp, A Gratwohl, P Imbach, P Maurice, L Tschopp, V von Fliedner, F Cavalli.   

Abstract

To investigate the value of maintenance chemotherapy after early consolidation treatment, an attempt was made to induce remission in 162 previously untreated patients, age-range 7-65 years (median 43). The 74 patients who were still in remission after early consolidation treatment (given for 3-5 months) were assigned to either maintenance chemotherapy every 8 weeks for 2 years or to observation only. After a median observation period of 44 months there was no difference between the groups in duration of remission or survival. Surprisingly, patients above 40 survived longer after early consolidation (median 4 years) than did patients aged 40 and below (median 1.6 years, p = 0.0002).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141436     DOI: 10.1016/s0140-6736(84)90424-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Authors:  Lisa M Hess; Nan Rong; Patrick O Monahan; Paridha Gupta; Champ Thomaskutty; Daniela Matei
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

Review 2.  Drug treatment of acute leukaemia. Current status.

Authors:  S M Donohue; C P Charlton
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

3.  A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.

Authors:  F Mandelli; M L Vegna; G Avvisati; S Amadori; A Spadea; E Cacciola; N Cantore; A De Laurenzi; C De Rosa; G Fioritoni
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

Review 4.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

5.  Therapy for acute myeloid leukemia in 119 adults: a comparison of two treatment protocols.

Authors:  H Link; H M Frauer; P Ostendorf; H D Waller
Journal:  Blut       Date:  1985-07

Review 6.  Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy.

Authors:  T Buechner; W Hiddemann
Journal:  Blut       Date:  1990-02

Review 7.  [Post-remission treatment of acute leukemia in adulthood: allogeneic bone marrow transplantation or chemotherapy?].

Authors:  U Jehn; R Grunewald
Journal:  Klin Wochenschr       Date:  1988-07-15

Review 8.  Older adults with acute myeloid leukemia.

Authors:  Mikkael A Sekeres; Richard Stone
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  Factors associated with transfusion requirements during treatment for acute myelogenous leukemia.

Authors:  G Favre; M Fopp; J Gmür; A Tichelli; M F Fey; A Tobler; E Schatzmann; A Gratwohl
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

10.  Acute promyelocytic leukemia.

Authors:  E C Kingsley; B G Durie; H S Garewal
Journal:  West J Med       Date:  1987-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.